These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7691988)

  • 41. The Epstein-Barr virus open reading frame BDLF3 codes for a 100-150 kDa glycoprotein.
    Nolan LA; Morgan AJ
    J Gen Virol; 1995 Jun; 76 ( Pt 6)():1381-92. PubMed ID: 7782767
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of the human cytomegalovirus 65K tegument phosphoprotein in insect cells by baculovirus vectors.
    La Fauci G; Sapienza VJ; Chen CJ; Wisniewski HM; Kim KS
    J Gen Virol; 1994 Jan; 75 ( Pt 1)():189-92. PubMed ID: 8113727
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel tetrameric gp350 1-470 as a potential Epstein-Barr virus vaccine.
    Cui X; Cao Z; Sen G; Chattopadhyay G; Fuller DH; Fuller JT; Snapper DM; Snow AL; Mond JJ; Snapper CM
    Vaccine; 2013 Jun; 31(30):3039-45. PubMed ID: 23665339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression and secretion in yeast of a 400-kDa envelope glycoprotein derived from Epstein-Barr virus.
    Schultz LD; Tanner J; Hofmann KJ; Emini EA; Condra JH; Jones RE; Kieff E; Ellis RW
    Gene; 1987; 54(1):113-23. PubMed ID: 3038696
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A chimeric EBV gp350/220-based VLP replicates the virion B-cell attachment mechanism and elicits long-lasting neutralizing antibodies in mice.
    Ogembo JG; Muraswki MR; McGinnes LW; Parcharidou A; Sutiwisesak R; Tison T; Avendano J; Agnani D; Finberg RW; Morrison TG; Fingeroth JD
    J Transl Med; 2015 Feb; 13():50. PubMed ID: 25885535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neutralizing monoclonal antibodies to bovine viral diarrhoea virus bind to the 56K to 58K glycoprotein.
    Donis RO; Corapi W; Dubovi EJ
    J Gen Virol; 1988 Jan; 69 ( Pt 1)():77-86. PubMed ID: 2447228
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Studies on Epstein-Barr virus strain differences with monoclonal antibodies].
    Yang ZH
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1989 Feb; 11(1):41-5. PubMed ID: 2548745
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Purification and quantification of recombinant Epstein-Barr viral glycoproteins gp350/220 from Chinese hamster ovary cells.
    Hessing M; van Schijndel HB; van Grunsven WM; Wolf H; Middeldorp JM
    J Chromatogr; 1992 May; 599(1-2):267-72. PubMed ID: 1320046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A unique conformation at the carboxyl terminus of the small hepatitis delta antigen revealed by a specific monoclonal antibody.
    Hwang SB; Lai MM
    Virology; 1993 Apr; 193(2):924-31. PubMed ID: 8460494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells.
    Turk SM; Jiang R; Chesnokova LS; Hutt-Fletcher LM
    J Virol; 2006 Oct; 80(19):9628-33. PubMed ID: 16973566
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stable expression of EBV-gp350 on the surface of NC37 cells confers natural killer (NK)-cell susceptibility or resistance, depending on the assay used to assess NK-mediated function.
    Sumonwiriya M; Horhthongkham N; Pattanapanyasat K; Ampol S; Sutthent R; Kantakamalakul W
    J Virol Methods; 2009 Oct; 161(1):154-60. PubMed ID: 19539652
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2).
    Nemerow GR; Houghten RA; Moore MD; Cooper NR
    Cell; 1989 Feb; 56(3):369-77. PubMed ID: 2464439
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein-Barr virus vaccine in healthy adults.
    Moutschen M; Léonard P; Sokal EM; Smets F; Haumont M; Mazzu P; Bollen A; Denamur F; Peeters P; Dubin G; Denis M
    Vaccine; 2007 Jun; 25(24):4697-705. PubMed ID: 17485150
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK; Fachiroh J; Artama WT; van Benthem E; Haryana SM; Middeldorp JM
    J Med Virol; 2007 Nov; 79(11):1710-21. PubMed ID: 17854043
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
    Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
    J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression, purification and immunodetection of a recombinant fragment (residues 179-281) of the G protein from rabies virus ERA strain.
    Bassi EJ; Vernal J; Zanluca C; Terenzi H; Zanetti CR
    Protein Expr Purif; 2008 Jun; 59(2):309-13. PubMed ID: 18406167
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conformation of the VP2 protein of bluetongue virus (BTV) determines the involvement in virus neutralization of highly conserved epitopes within the BTV serogroup.
    White JR; Eaton BT
    J Gen Virol; 1990 Jun; 71 ( Pt 6)():1325-32. PubMed ID: 1693664
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Expression and immunogenic characterization of recombinant gp350 for developing a subunit vaccine against Epstein-Barr virus.
    Wang M; Jiang S; Han Z; Zhao B; Wang L; Zhou Z; Wang Y
    Appl Microbiol Biotechnol; 2016 Feb; 100(3):1221-1230. PubMed ID: 26433969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    Thorley-Lawson DA; Poodry CA
    J Virol; 1982 Aug; 43(2):730-6. PubMed ID: 6287039
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.
    Urquiza M; Lopez R; Patiño H; Rosas JE; Patarroyo ME
    J Biol Chem; 2005 Oct; 280(42):35598-605. PubMed ID: 16087675
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.